US FDA Warning Letter Draws Indian Solvent Recycler Into Valsartan Crisis
Executive Summary
Lantech’s solvent recovery operations expected to meet US drug GMP requirements due to risk of carcinogens in blood pressure medications.
You may also be interested in...
FDA Warning Letter Blasts Mylan’s Lax API Impurity Controls
Concerned about another possible nitrosamine scare, the US FDA has sent a warning letter to Mylan focusing on the firm’s failure to control contamination risks of its APIs and inadequate testing of reused solvents.
FDA Warning Letter Blasts Mylan’s Continued Lax Impurity Controls for APIs
Concerned about another possible nitrosamine scare, US FDA warning letter to Mylan focuses on firm’s failure to control contamination risks of its APIs and its inadequate testing of reused solvents.
EU Takes Lessons From Valsartan Crisis
EU report on “lessons learnt” from the valsartan crisis calls for tighter GMP controls on API suppliers.